Merck & Co. (NYSE:MRK)‘s stock had its “buy” rating reiterated by stock analysts at Bank of America in a report issued on Thursday. They currently have a $62.00 target price on the stock. Bank of America’s target price indicates a potential upside of 9.39% from the stock’s previous close. Merck & Co., Inc. (NYSE:MRK) shares after opening at $57.61 moved to $57.85 on last trade day and at the end of the day closed at $56.68. Company price to sales ratio in past twelve months was calculated as 3.79 and price to cash ratio as 9.53. Merck & Co., Inc. (NYSE:MRK) showed a negative weekly performance of -1.00%.
Pfizer’s offer, quickly rebuffed by AstraZeneca as too low, was revealed after a pair of experimental drugs thought to have billion-dollar potential for Pfizer, Eliquis and Xeljanz (PFE:US), fizzled in their starts and a third, the breast cancer treatment palbociclib, will soon face a potent competitor in Eli Lilly & Co.’s experimental drug bemaciclib. Pfizer Inc. (NYSE:PFE) shares advanced 4.20% in last trading session and ended the day on $32.04. PFE return on equity ratio is recorded as 52.60% and its return on assets is 23.20%. Pfizer Inc. (NYSE:PFE) yearly performance is 9.99%.
Bristol-Myers Squibb Company (NYSE:BMY) will host a conference call at 9:00 AM ET on April 29, 2014, to discuss its Q1 14 earnings results.Bristol-Myers Squibb Co (NYSE:BMY) shares moved down -0.28% in last trading session and was closed at $50.36, while trading in range of $49.40-$51.22. Bristol-Myers Squibb Co (NYSE:BMY) year to date performance is -4.59%.
AbbVie (NASDAQ:ABBV)‘s stock had its “buy” rating reaffirmed by investment analysts at Bank of America in a note issued to investors on Thursday. They currently have a $55.00 target price on the stock. Bank of America’s price objective would suggest a potential upside of 11.93% from the stock’s previous close. AbbVie Inc (NYSE:ABBV) weekly performance is 2.91%. On last trading day company shares ended up $50.87. AbbVie Inc (NYSE:ABBV) distance from 50-day simple moving average is 0.71%. Analysts mean target price for the company is $53.32.
Leave a Reply